Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Centre of Chinese Medicine, Georgia Rea Rehabilitation Centre, Georgia |
---|---|
Information provided by: | Centre of Chinese Medicine, Georgia |
ClinicalTrials.gov Identifier: | NCT00153270 |
The purpose of this study is to determine whether antiepileptic drug sodium valproate is effective in the treatment of chronic asthma.
Condition | Intervention | Phase |
---|---|---|
Bronchial Asthma |
Drug: Sodium Valproate |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Sodium Valproate Efficacy in Asthma Therapy |
Estimated Enrollment: | 46 |
Study Start Date: | September 2000 |
Estimated Study Completion Date: | April 2001 |
Effective therapy of asthma still remains quite serious problem. According GINA definition, asthma is an inflammatory disorder. Consequently, modern pharmacotherapy of asthma provides wide use of anti-inflammatory drugs. But asthma also is a paroxysmal disorder: many specialists and even some guidelines underline paroxysmal clinical picture of asthma. Besides this, according to some authors, neurogenic inflammation may play important role in asthma mechanism. But some other neurogenic inflammatory paroxysmal disorders exist, and they are migraine and trigeminal neuralgia. Some antiepileptic drugs, like carbamazepine and valproate, are very effective in therapy of migraine and trigeminal neuralgia – more than in 80% of cases. If bronchial asthma also is paroxysmal inflammatory disease, like migraine and trigeminal neuralgia, it is possible that some antiepileptic drugs also are very effective in asthma therapy.
We performed a double-blind, placebo-controlled 3-month trial for evaluation of sodium valproate efficacy in therapy of bronchial asthma. Sodium Valproate is antiepileptic drug of new generation, initially produced by Sanofi Pharma. Comparison: Patients received investigational drug in addition to their usual routine antiasthmatic treatment, compared to patients received placebo in addition to their usual routine antiasthmatic treatment.
Ages Eligible for Study: | 16 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Principal Investigator: | Merab Lomia, MD | "Rea" Rehabilitation Centre |
Study Chair: | Manana Tchaia, MD | Centre of Chinese Medicine |
Study ID Numbers: | LPT-1000-SV-0201 |
Study First Received: | September 8, 2005 |
Last Updated: | May 15, 2006 |
ClinicalTrials.gov Identifier: | NCT00153270 |
Health Authority: | Georgia: Ministry of Health |
Bronchial asthma Sodium valproate Antiepileptic drug Efficacy |
Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Hypersensitivity, Immediate Asthma Valproic Acid Respiratory Hypersensitivity |
Neurotransmitter Agents Tranquilizing Agents Bronchial Diseases Immune System Diseases Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants |
Enzyme Inhibitors Antimanic Agents Pharmacologic Actions Therapeutic Uses GABA Agents Central Nervous System Agents Anticonvulsants |